Renal dose adjuster
Automatic dose adjustment is unavailable. CKD stage alone does not establish a safe drug dose or interval. Review a creatinine range below, then use current drug-specific references and patient assessment for dosing.
Safety checks
- This tool supports calculation and education only.
- It does not diagnose, prescribe, or replace clinical judgment.
- CKD stage is not a measured GFR or a universal drug-clearance factor.
- No automatic dosing, interval selection, or drug-class recommendation is provided.
- Always consult current formulary and pharmacology references.
Basis and limits
- IRIS 2026, dogs: Stage 1 <1.4; Stage 2 1.4–2.8; Stage 3 2.9–5.0; Stage 4 >5.0 mg/dL.
- IRIS 2026, cats: Stage 1 <1.6; Stage 2 1.6–2.8; Stage 3 2.9–5.0; Stage 4 >5.0 mg/dL.
- µmol/L, dogs: Stage 1 <125; Stage 2 125–250; Stage 3 251–440; Stage 4 >440.
- µmol/L, cats: Stage 1 <140; Stage 2 140–250; Stage 3 251–440; Stage 4 >440.
- Precision: a value between 2.8 and 2.9 mg/dL or between 250 and 251 µmol/L is flagged for review rather than silently rounded. Near a cutoff, confirm laboratory reporting precision and interpret serial creatinine and SDMA together.
- SDMA: persistent discordance may change the stage and treatment category. The IRIS SDMA recommendations use the IDEXX assay; equivalent results from other assays are not established.
- Low creatinine: a Stage 1 creatinine range alone does not establish CKD. Other evidence of renal abnormality is needed.
Reference audit trail
Reference details will appear here after review.
Last reviewed: IRIS 2026 source checked. Owner-approved: 16 October 2026. Next review: by 16 October 2027, or sooner if guidance changes. Owner approval is not external veterinary clinical sign-off.
References: IRIS Staging of CKD (Modified 2026), pages 1–4; IRIS guidelines and treatment recommendations (2026). These sources support staging and individualized assessment, not universal dose multipliers. Consult a current drug-specific formulary for prescribing. Report a clinical concern.